爱威科技(688067.SH)：上半年净利润1405.54万元，同比增长21.16%

Core Viewpoint - Aiwai Technology (688067.SH) reported a revenue of 110 million yuan for the first half of 2025, reflecting a year-on-year growth of 12.70%, driven by strong sales of its reproductive tract secretion analyzers and related consumables, as well as the upcoming launch of its blood analysis production line in 2024 [1] Financial Performance - The company achieved a net profit attributable to shareholders of 14.0554 million yuan, marking a year-on-year increase of 21.16% [1] - The net profit excluding non-recurring gains and losses was 11.3846 million yuan, which represents a year-on-year growth of 37.24% [1] - Basic earnings per share stood at 0.21 yuan [1] Revenue Growth Drivers - The revenue growth of 12.70% was primarily due to the strong sales performance of the reproductive tract secretion analyzers and related consumables, as well as the anticipated launch of the blood analysis production line in 2024 [1] Profit Growth Factors - The net profit increase of 21.16% was attributed to: 1. The net profit grew in line with revenue, while the company's cost control system implemented in November of the previous year allowed for precise expense management, resulting in a lower growth rate of period expenses compared to revenue [1] 2. The company undertook various cost reduction and efficiency enhancement measures across R&D, procurement, and manufacturing, leading to a decrease in the cost of main products [1]